Results 121 to 130 of about 4,498 (182)

Cobicistat, a pharmacoenhancer for HIV treatments

Drugs of Today, 2013
Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition. In addition, its water solubility may lend itself to coformulation with other drugs.
openaire   +2 more sources

Darunavir/cobicistat once daily for the treatment of HIV

Expert Review of Anti-infective Therapy, 2015
A current focus in HIV management is improving adherence by minimizing pill burden with convenient formulations, including fixed-dose combinations (FDCs). Darunavir, a HIV protease inhibitor, co-administered with low-dose ritonavir (800/100 mg once daily), is recommended in guidelines in combination with other antiretrovirals for HIV patients with no ...
Thomas N, Kakuda, Herta, Crauwels, Magda, Opsomer, Frank, Tomaka, Tom, van de Casteele, Simon, Vanveggel, Koen, Iterbeke, Goedele, de Smedt   +7 more
openaire   +2 more sources

Cobicistat: a new opportunity in the treatment of HIV disease?

Expert Opinion on Pharmacotherapy, 2014
Cobicistat (Cobi), a selective novel CYP3A4 inhibitor, is an orally administered, non-antiretroviral pharmacokinetic enhancer which boosts the plasma levels of several drugs, including HIV-1 protease inhibitors and the integrase strand transfer inhibitor elvitegravir (ELV).PubMed and www.clinicaltrials.gov were searched with the term 'cobicistat' for ...
Amedeo, Capetti, Giuliano, Rizzardini
openaire   +2 more sources

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.

AIDS reviews, 2016
Rezolsta® (darunavir/cobicistat) is the first boosted protease inhibitor in a fixed-dose combination to be approved for the treatment of HIV infection. It contains darunavir, a protease inhibitor with a well-known safety and efficacy profile, and the new pharmacokinetic enhancer cobicistat.
Adrián, Curran, Ignacio, Pérez-Valero, José, Moltó   +2 more
openaire   +1 more source

Atazanavir/cobicistat

Reactions Weekly, 2021
openaire   +1 more source

Cobicistat/darunavir

Reactions Weekly, 2019
openaire   +2 more sources

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial

Lung Cancer, 2022
Anne-Marie Dingemans, Lizza Hendriks, Egbert Smit   +2 more
exaly  

Elvitegravir/cobicistat, mirabegron, and linaclotide

Journal of the American Pharmacists Association, 2012
Daniel A, Hussar, Loren N, Martinez
openaire   +2 more sources

Atorvastatin/cobicistat interaction

Reactions Weekly, 2022
openaire   +1 more source

Cobicistat/glucocorticoids interaction

Reactions Weekly, 2021
openaire   +1 more source